These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 11496457)
1. And on the cover of the guide were two words in red--don't panic. Harvey R Aust Health Rev; 2001; 24(2):15-20. PubMed ID: 11496457 [No Abstract] [Full Text] [Related]
2. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency? Viney R Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466 [No Abstract] [Full Text] [Related]
3. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else. Dalton A Aust Health Rev; 2001; 24(2):7-14. PubMed ID: 11496474 [No Abstract] [Full Text] [Related]
4. Easy ride for drug industry. McBane M Health Aff (Millwood); 2003; 22(4):259-60. PubMed ID: 12889775 [No Abstract] [Full Text] [Related]
5. The pharmaceutical situation in the Philippines. Hartigan-Go K Aust Health Rev; 2001; 24(2):25-31. PubMed ID: 11496467 [No Abstract] [Full Text] [Related]
6. The subsidy of pharmaceuticals in Australia: processes and challenges. Sansom L Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399 [TBL] [Abstract][Full Text] [Related]
7. A catastrophe in health care. Cassels A Can Nurse; 2009 Nov; 105(9):52. PubMed ID: 19998693 [No Abstract] [Full Text] [Related]
8. Implications for managed care organizations of the Merck and Medco consent. Pollard MR; Tilson HH Med Interface; 1996 Mar; 9(3):60-2. PubMed ID: 10184511 [No Abstract] [Full Text] [Related]
9. Implications of the Australian guidelines for the United States. Freund DA; Evans D; Henry D; Dittus R Health Aff (Millwood); 1992; 11(4):202-6. PubMed ID: 1483641 [No Abstract] [Full Text] [Related]
10. Basing prescription drug payment on economic analysis: the case of Australia. Drummond MF Health Aff (Millwood); 1992; 11(4):191-6. PubMed ID: 1483639 [No Abstract] [Full Text] [Related]
11. Uneasy alliance--clinical investigators and the pharmaceutical industry. Bodenheimer T N Engl J Med; 2000 May; 342(20):1539-44. PubMed ID: 10816196 [No Abstract] [Full Text] [Related]
12. Drug policy down under: Australia's pharmaceutical benefits scheme. Duckett SJ Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996 [TBL] [Abstract][Full Text] [Related]
13. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. Bell KD Med J Aust; 1995 Apr; 162(8):447; author reply 447-8. PubMed ID: 7746194 [No Abstract] [Full Text] [Related]
14. [Authorization and reimbursement of orphan drugs in an international comparison]. Roll K; Stargardt T; Schreyögg J Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380 [TBL] [Abstract][Full Text] [Related]
15. Study critiques corporate control of trials. Niiler E Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659 [No Abstract] [Full Text] [Related]